



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/784,900	02/24/2004	Eugene R. Cooper	029318-1003	1015
31049 7590 09/20/2007 ELAN DRUG DELIVERY, INC. C/O FOLEY & LARDNER LLP 3000 K STREET, N.W. SUITE 500 WASHINGTON, DC 20007-5109			EXAMINER TRAN, SUSAN T	
			ART UNIT 1615	PAPER NUMBER
			MAIL DATE 09/20/2007	DELIVERY MODE PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/784,900

Applicant(s)

COOPER ET AL.

Examiner

Susan T. Tran

Art Unit

1615

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 26 June 2007.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-72 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-72 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION***Double Patenting***

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1-26 and 31-72 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-34 of U.S. Patent No. 6,908,626 ('626) in view of Meyer et al. USPN 6,221,377 ('377). The '626 patent claimed a formulation comprising: nanoparticulate of active agent having an effective average particle size of less than about 1 micron; and (b) at least one surface stabilizer adsorbed onto the surface of the nanoparticulate active agent particles wherein the concentration of the surface stabilizer is from about 0.5% to about 99.999%(w/w), based upon the total weight of the nanoparticulate active agent and the surface stabilizer, and wherein the surface stabilizer is selected from the group consisting of a nonionic surface

Art Unit: 1615

stabilizer, an anionic surface stabilizer, a cationic surface stabilizer, and an ionic surface stabilizer. Average particle size in nanometer is found in claim 2. Active agent is found in claim 19. Surface stabilizer is found in claims 20-22. Dosage formulations are found in claims 11-17. Method of making the formulation is found in claim 25. Method of treating a mammal is found in claim 34. The '626 patent does not expressly disclose meloxicam as an active agent.

Meyer teaches analgesic agent includes meloxicam (column 6, lines 18-67; and claim 47). Thus, it would have been obvious to one of ordinary skill in the art to modify the formulation of the '626 patent to include meloxicam as an active agent, because Meyer teaches meloxicam is a well known analgesic agent, because the '626 patent teaches a formulation suitable for a wide variety of active agents including analgesic.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1-17, 26-42, 50-67 are rejected under 35 U.S.C. 103(a) as being unpatentable over Liversidge et al. WO 93/25190, in view of Meyer et al. US 6,221,377.

Liversidge teaches a dispersible nanoparticle having an effective average particle size of less than about 400 nm, the nanoparticle comprising NSAID and surface modifier (abstract; and page 2, lines 21-25). NSAID is present in crystalline phase, and

Art Unit: 1615

in an amount 0.1%-60% (page 3, lines 31-35; and page 7, lines 31-33). Liversidge further teaches a pharmaceutical formulation for the treatment of a mammal, the formulation comprising the dispersible nanoparticle, and an acceptable carrier (page 2, lines 26-28). Liversidge also teaches a process for preparing the nanoparticle comprising the steps of dispersing an NSAID in a liquid dispersion medium; wet grinding the NSAID in the presence of grinding media, wherein the pH of said medium is within the range of 2-6; and adding surface modifier in an amount of 0.1-90% (page 7, lines 20 through column 8, lines 1-17; and pages 9-10). The claimed surface modifier is disclosed in pages 5-6. Two or more surface modifiers can be used in combination (ID). The pharmaceutical formulation can be processed into dosage form such as solid, liquid for administration by parenteral, oral, rectal, and the like (page 11, lines 29-36).

Liversidge does not explicitly teach the claimed meloxicam.

Meyer teaches dosage form comprising analgesic or NSAID includes oxicams such as meloxicam, piroxicam and isoxicam (column 6, lines 38-42). Thus, it would have been obvious to one of ordinary skill in the art to modify the formulation of Liversidge using meloxicam in view of the teaching of Meyer, because Meyer teaches the equivalency of meloxicam, piroxicam, and isoxicam, and because Liversidge teaches a formulation suitable for drugs including oxicams.

It is noted that Liversidge does not expressly teach the claimed release profile, and the claimed C_{max} . However, absent of evidence to the contrary, the burden is shifted to applicant to show that the formulation taught by Liversidge does not have the

Art Unit: 1615

claimed release profile. This is because Liversidge teaches a nanoparticle formulation using the claimed surface modifier, carrier, and parameters.

Claims 1-17, 26-42, 50-67 are rejected under 35 U.S.C. 103(a) as being unpatentable over Ryde et al. US 6,375,986, in view of Meyer et al. US 6,221,377.

Ryde teaches a solid dosage form comprising nanoparticulate composition comprising poorly water soluble active agent, at least one polymeric surface stabilizer, and (DOSS) (see abstract, column 6, lines 53-67). The nano-particle having diameter less than 1 μm (column 6, lines 24-34), wherein at least 90% of the nano-particle population having diameter of less than 200 nm (column 7, lines 63 through column 8, lines 1-5). The surface stabilizers is disclosed in column 7, lines 33-53, which can be used in a concentration from 0.01 to about 90% (column 9, lines 18-22). The active agent is used in a concentration of about 99.8 to about 0.1% (column 9, lines 24-28). The nano-particle can be made by method selected from milling, precipitation, drying dispersion, high shear granulation, fluid bed granulation, and spray coating (column 9, lines 38 through column 10, lines 1-41). The dosage form can be administered rectally, intravaginally, or orally in the form of tablet, powder, capsule, pills, and granule (column 10, lines 45-67).

Ryde does not explicitly teach the claimed meloxicam.

Meyer teaches dosage form comprising analgesic or NSAID includes oxicams such as meloxicam, piroxicam and isoxicam (column 6, lines 38-42). Thus, it would have been obvious to one of ordinary skill in the art to modify the formulation taught by

Art Unit: 1615

Ryde using meloxicam in view of the teaching of Meyer, because Meyer teaches analgesic agents including meloxicam, and because Ryde teaches a formulation suitable for a variety of drugs including analgesic (claim 14).

It is noted that Ryde does not expressly teach the claimed release profile, and the claimed C_{max} . However, absent of evidence to the contrary, the burden is shifted to applicant to show that the formulation taught by Ryde does not have the claimed release profile. This is because Ryde teaches a nanoparticle formulation using the claimed surface modifier, carrier, and parameters.

Claims 18-25, 43-49 and 68-72 are rejected under 35 U.S.C. 103(a) as being unpatentable over Liversidge et al. or Ryde et al. US 6,375,986, in view of Desai et al. WO 01/45706 A1 or Courteille et al. US 5,384,124.

Liversidge and Ryde are relied upon for the reasons stated above. The cited references do not teach the second particle population.

Desai teaches a dual-release composition of low water soluble drug (COX-2 inhibitor) comprising first fraction of the drug in nano-particulate form having average diameter of about 200 to about 400 nm and a D90 particle size less than about 5 μm (page 18); and a second fraction of the drug in micro-particulate form having D10 particle size of between 25 to about 100 μm (page 20, 1st paragraph). The first fraction nano-particle drug can be present alone or in combination with one or more excipient, such as nano-particles of the drug have a surface modifying agent (PEG-400) adsorbed on the surface thereof (page 18, 3rd through page 19). The weight ratio of the first to the

second fraction of the drug in the composition is about 1:10 to about 10:1 (page 22, 3rd paragraph). The composition can be in an oral dosage form including tablet, pills, hard or soft capsule, lozenges, cachets, dispensable powder, granule, suspension or elixir (pages 37-38).

Courteille teaches a solid unitary composition comprising combination of nano-particle having diameter of less than 1 μm and micro-particle having diameter of between 1 μm to 2 mm (see abstract, column 2, lines 32-46). The mixture of nano/micro-particle contains one or more active agents of the same or different type (column 1, lines 66-68, and column 2, lines 23-31). The active agent can be selected from antibiotic, analgesic, tranquilizer, vitamins, and therapeutic agents for diseases of allergies, hormones, or gastrointestinal tract (column 5, lines 46-66). The mixture of nano/micro-particle is prepared by any known method (air-fluidized bed coating, turbine coating, simple extrusion, or micro-encapsulation) employing the use of a polymer or a macromolecular substance (surface stabilizer) selected from the group of cellulose derivatives, starch, polyamide, collagen, dextrin, gelatin, polyvinyl chloride or the like (column 2, lines 46-55, and column 3, lines 18-40). The mixture further comprises stabilizing agent, surfactant, and biding agent (column 4, lines 20 through column 5, lines 1-28). Courteille further teaches the solid dosage form comprises immediate release with a secondary controlled release of mixture of nano/micro-particle (column 6, lines 16-50). The solid dosage form is to be incorporated into pharmaceutical oral dosage form (column 6, lines 51-56).

Thus, it would have been obvious to one of ordinary skill in the art to modify the composition of Liversidge or Ryde to include the second particle population in view of the teachings of Desai or Courteille, because Desai and Courteille teaches compositions suitable for analgesic drugs including COX inhibitor, and because Liversidge and Ryde teach the desirability of obtaining composition suitable for NSAID active agents.

Response to Arguments

Applicant's arguments filed 06/26/07 have been fully considered but they are not persuasive.

Applicant argues that the amendments to claim 1 obviate the nonstatutory obviousness-type double patenting rejection, and withdrawal of the rejection is respectfully requested.

However, the properties recited in claim 1 does not impart patentability differences between the present claims and those of US '626 to obviate the obviousness double patenting rejection. This is because the '626 patent teaches the desirability to improve solubility and bioavailability of water-insoluble drug by preparing a nanoparticulate formulation similar to the present claimed invention, namely, nanoparticulate of active agent having an effective average particle size of less than about 1 micron; and (b) at least one surface stabilizer adsorbed onto the surface of the nanoparticulate active agent particles wherein the concentration of the surface stabilizer is from about 0.5% to about 99.999%(w/w), based upon the total weight of the

Art Unit: 1615

nanoparticulate active agent and the surface stabilizer, and wherein the surface stabilizer is selected from the group consisting of a nonionic surface stabilizer, an anionic surface stabilizer, a cationic surface stabilizer, and an ionic surface stabilizer (see for example, claims 1, 2, 11-25 and 34). Accordingly, the properties desired by the applicant are necessitated by the nanoparticles having the same effective average particle size, and by the use of the same surface stabilizer. For at least these reasons, the obviousness double patenting rejection over the '626 patent is maintained.

Applicant argues that neither Liversidge nor Meyer, alone or in combination, teach each and every claimed feature, because claim 1 as amended requires the meloxicam composition of the invention to have, in comparative pharmacokinetic testing with a non-nanoparticulate formulation of meloxicam of the same dosage strength and form, a smaller T_{max} when compared to a T_{max} of the non-nanoparticulate meloxicam formulation. As acknowledged by the examiner, neither Liversidge nor Meyer alone or in combination fairly teach or suggest any such pharmacokinetic feature, let alone the specifically claimed T_{max} , C_{max} , and release profiles. For at least this reason, the rejection of record has been overcome.

However, in response to applicant's argument, it is noted that where the claimed and prior art products are identical or substantially identical in structure or composition, or are produced by identical or substantially identical processes, a prima facie case of either anticipation or obviousness has been established. *In re Best*, 562 F.2d 1252, 1255, 195 USPQ 430, 433 (CCPA 1977). In the present case, Liversidge teaches a similar nanoparticulate formulation having the same effective average particle diameter

with the use of the same surface stabilizer. Therefore, the properties desired by the applicant are necessitated by the nanoparticles having the same effective average particle size with the use of the same surface stabilizer. Products of identical chemical composition cannot have mutually exclusive properties. A chemical composition and its properties are inseparable. Further, Liversidge is cited in combination with Meyer for the teaching of the claimed NSAID, meloxicam. Thus, the burden is shifted to applicant to show that the nanoparticulate formulation taught by Liversidge does not necessarily have the claimed properties. When the PTO shows a sound basis for believing that the products of the applicant and the prior art are the same, the applicant has the burden of showing that they are not. *In re Spada*, 911 F.2d 705, 709, 15 USPQ2d 1655, 1658 (Fed. Cir. 1990).

Applicant argues that the examiner considers such pharmacokinetic features of the claimed meloxicam composition inherent. MPEP §2163.07(a) and MPEP § 2112IV provide that if the examiner relies upon the theory of inherency, "the examiner must provide a basis in fact and/or technical reasoning to reasonably support the determination that the allegedly inherent characteristic necessarily flows from the teachings of the applied prior art." *Ex parte Levy*, 17 USPQ2d 1461, 1464 (Bd. Pat. App. & Inter. 1990). MPEP § 2112V provides that only when 1) the referenced product and the claimed invention are proven substantially identical, and 2) the examiner has provided evidence or reasoning tending to show the alleged inherent characteristic, *then the burden shifts to the applicant to show an unobvious difference*. The present rejection lacks any basis in fact and/or technical reasoning to reasonably support the

examiner's conclusion that the claimed pharmacokinetic features of T_{max} , release profile, and C_{max} are characteristics that necessarily flow from the teachings of the applied prior art. Accordingly, the burden to show an unobvious difference has not shifted to the applicants. The cited MPEP sections mandate withdrawal of the rejection.

However, as admitted by the applicant at page 29 of the Remarks filed 06/26/07, *"the skilled artisan would have appreciated, C_{max} represents the maximum concentration of a drug in the plasma, and T_{max} stands for the time to reach the maximum concentration. C_{max} and T_{max} are well-known pharmacokinetic features of a drug that one of ordinary skill in the art would identify when studying how the body reacts to the drug in a particular drug form"*. Thus, given the above reasons, and the suggestion for preparing nanoparticles using the same parameters by Liversidge, one of ordinary skill in the art would have been motivated to obtain C_{max} and T_{max} that would fall within the claimed range.

Applicant argues that Meyer is not in the context of making a nanoparticulate active agent composition but describes enhancing the effect of an analgesic, anti-inflammatory and/or anti-pyretic response-producing effective amount of a medicament with the aid of nitrous oxide in the administration medium. There is only one general statement in the Meyer patent that oxicams include meloxicam, piroxicam and isoxicam. It appears that the stated rationale in the rejection is that Liversidge discloses a nanoparticulate NSAID composition and meloxicam belongs to the NSAID genus, hence, the prior art renders the claimed nanoparticulate meloxicam species obvious.

In response to applicant's argument, the test for obviousness is not whether the features of a secondary reference may be bodily incorporated into the structure of the primary reference; nor is it that the claimed invention must be expressly suggested in any one or all of the references. Rather, the test is what the combined teachings of the references would have suggested to those of ordinary skill in the art. See *In re Keller*, 642 F.2d 413, 208 USPQ 871 (CCPA 1981). Liversidge teaches a delivery system suitable for a wide variety of drugs including NSAID. Myer is relied upon for the teaching of meloxicam as an NSAID.

Applicant argues that Ryde does not specifically teach a nanoparticulate meloxicam composition and Ryde's composition requires the presence of DOSS. In fact, Ryde further describes that the presence of DOSS is essential because DOSS and the polymeric surface stabilizer exhibit a synergistic effect in redispersion of the solid dose nanoparticulate active agent composition. By contrast, the claimed nanoparticulate meloxicam composition is not limited to a solid dose and does not require DOSS as an ingredient.

In response to applicant argument, the transitional phrase "comprising of" in the preamble of the claim does not preclude the presence of DOSS. Further, in response to applicant's argument that the reference fails to show certain features of applicant's invention, it is noted that the features upon which applicant relies (i.e., the claimed nanoparticulate meloxicam composition is not limited to a solid dose and does not require DOSS as an ingredient) are not recited in the rejected claims. Although the claims are interpreted in light of the specification, limitations from the specification are

not read into the claims. See *In re Van Geuns*, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993).

Conclusion

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Correspondence

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Susan T. Tran whose telephone number is (571) 272-0606. The examiner can normally be reached on M-F 6:00 am to 4:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Woodward can be reached on (571) 272-8373. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1615

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Art Unit 1615


SUSAN TRAN
PRIMARY EXAMINER